Gene therapy for chronic granulomatous disease
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Chronic granulomatous disease (CGD) is a congenital immune deficiency that is a promising therapeutic target for gene replacement into haematopoietic stem cells (HSCs). CGD results from mutations in any one of four genes encoding subunits of the superoxide-generating NADPH oxidase of phagocytes. Life-threatening, recurrent bacterial and fungal infections, as well as inflammatory granulomas, are the hallmarks of the disease. NADPH oxidase activity can be reconstituted by retroviral- or lentiviral-mediated gene transfer to human CGD marrow in vitro and in xenograft transplant models. Gene transfer studies in knockout mouse models that resemble the human disease suggest that correction of oxidase activity in a minority of phagocytes will be of clinical benefit. Phase I clinical studies in unconditioned CGD patients showed transient expression of small numbers of gene-corrected neutrophils. Areas of research at present include efforts to enhance gene transfer rates into repopulating HSCs using vectors that transduce quiescent cells, and to increase the engraftment of genetically corrected HSCs using non-myeloablative conditioning and drug resistance genes for selection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
HIV-1 Integration in the Human Genome Favors Active Genes and Local Hotspots
Schröder, A. R. W., Shinn, P., Chen, H., Berry, C., Ecker, J. R., & Bushman, F. (2002) · Cell · doi:10.1016/s0092-8674(02)00864-4 · Cited by 1,832
Chronic Granulomatous Disease: Report on a National Registry of 368 Patients
Winkelstein, J. A., Marino, M. C., Johnston, R. B., Boyle, J., Curnutte, J., Gallin, J. I., Malech, H. L., Holland, S. M., Ochs, H., Quie, P., et al. (2000) · Medicine · doi:10.1097/00005792-200005000-00003 · Cited by 1,728
Transcription Start Regions in the Human Genome Are Favored Targets for MLV Integration
Wu, X., Li, Y., Crise, B., & Burgess, S. M. (2003) · Science · doi:10.1126/science.1083413 · Cited by 1,305 · cited 1×
“A recent development of relevance to refining approaches for gene therapy is the recognition that both oncoretroviral and lentiviral vectors frequently integrate in or near genes [97,98], with the potential for disruption or alteration of cellular gene function, including effects of potent viral enhancers present in t…”
BackgroundPollock, J. D., Williams, D. A., Gifford, M. A. C., Li, L. L., Du, X., Fisherman, J., Orkin, S. H., Doerschuk, C. M., & Dinauer, M. C. (1995) · Nature Genetics · doi:10.1038/ng0295-202 · Cited by 921
Self-citationMay, C., Rivella, S., Callegari, J., Heller, G., Gaensler, K. M. L., Luzzatto, L., & Sadelain, M. (2000) · Nature · doi:10.1038/35017565 · Cited by 567 · cited 1×
“Recent studies suggest that vectors derived from lentiviruses will be useful for the correction of genetic blood diseases [75-80].”
BackgroundHelper virus induced T cell lymphoma in nonhuman primates after retroviral mediated gene transfer
Donahue, R. E., Kessler, S. W., Bodine, D., McDonagh, K., Dunbar, C., Goodman, S., Agricola, B., Byrne, E., Raffeld, M., & Moen, R. (1992) · The Journal of Experimental Medicine · doi:10.1084/jem.176.4.1125 · Cited by 532 · cited 1×
“Previous studies suggested that retroviral insertional mutagenesis, although a theoretical concern, was a rare event and required multiple gene disruptions or activations [99,100].”
BackgroundThe p47phox mouse knock-out model of chronic granulomatous disease.
Jackson, S. H., Gallin, J. I., & Holland, S. M. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.3.751 · Cited by 484
Heyworth, P. G., Cross, A. R., & Curnutte, J. T. (2003) · Current Opinion in Immunology · doi:10.1016/s0952-7915(03)00109-2 · Cited by 396
Morgenstern, D. E., Gifford, M. A. C., Li, L. L., Doerschuk, C. M., & Dinauer, M. C. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.185.2.207 · Cited by 370 · cited 1×
“Persistence of antigens inside granulomas, dysregulation of the inflammatory response, decreased production of anti-inflammatory mediators, as well as inefficient clearance of inflammatory debris [21-24] and chemotoxins [25], in the absence of ROS have been hypothesised.”
BackgroundSelf-citation
Cited by
Ott, M. G., Schmidt, M., Schwarzwaelder, K., Stein, S., Siler, U., Koehl, U., Glimm, H., Kühlcke, K., Schilz, A., Kunkel, H., et al. (2006) · Nature Medicine · doi:10.1038/nm1393 · Cited by 1,051
Kaufmann, K. B., Büning, H., Galy, A., Schambach, A., & Grez, M. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201202287 · Cited by 276
Ramsey, I. S., Ruchti, E., Kaczmarek, J. S., & Clapham, D. E. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902761106 · Cited by 259
Chronic granulomatous disease: a review of the infectious and inflammatory complications
Song, E., Jaishankar, G. B., Saleh, H., Jithpratuck, W., Sahni, R., & Krishnaswamy, G. (2011) · Clinical and Molecular Allergy · doi:10.1186/1476-7961-9-10 · Cited by 148
Graham, D. B., Robertson, C. M., Bautista, J., Mascarenhas, F., Diacovo, M. J., Montgrain, V., Lam, S. K., Cremasco, V., Dunne, W. M., Faccio, R., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32729 · Cited by 124
Metadata
- Authors
- Barese, C. N., Goebel, W. S., & Dinauer, M. C.
- Venue
- Expert Opinion on Biological Therapy
- Publisher
- Informa Healthcare
- Published
- 2004-09
- Volume
- 4
- Issue
- 9
- Pages
- 1423-1434
- ISSN
- 1471-2598 (ISSN-L)
- 1744-7682
- OpenAlex
- W1981092784
- Cited by
- 71
- References
- 9
- FWCI
- 3.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Gene therapy for chronic granulomatous disease. https://app.cochat.ai/papers/10.1517/14712598.4.9.1423
- The paper
- Barese, C. N., Goebel, W. S., & Dinauer, M. C. (2004). Gene therapy for chronic granulomatous disease. Expert Opinion on Biological Therapy. https://doi.org/10.1517/14712598.4.9.1423
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.